Summary
Ten hypertensive patients with moderate to severe impairment of renal function were treated with sotalol for 5 to 10 weeks (average 6.4 weeks). Dosage was individually titrated (range 80 to 480 mg daily). The drug was given once daily in the morning. In eight patients blood pressure was satisfactorily controlled. Higher steady-state levels were observed than have been reported after similar doses in patients with normal renal function. The apparent first-order elimination rate constant and plasma clearance were significantly correlated with glomerular filtration rate. For an anuric patient, serum half-life was calculated to be 69 h. In relation to the raised plasma levels, side effects were uncommon. Since sotalol is excreted predominantly via the kidney, therapy in patients with impaired renal function should start with a low dose and any increase in dosage should be made carefully. As the anti-hypertensive effect does not appear to be correlated with the plasma level or with tolerance, adjustment of dose should be based on clinical response.
Similar content being viewed by others
References
Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H (1976) Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 39: 118–128
Bodem G, Grieser H, Eichelbaum M, Gugler R (1974) Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol 7: 249–252
Bröchner-Mortensen J (1972) A simple method for determination of glomerular filtration rate. Scand J Clin Lab Invest 30: 271–274
Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Prog Pharmacology, Vol 1 No 4. Gustav Fischer, Stuttgart New York
Garrett E R, Schnelle K (1971) Separation and spectrofluometric assay of the beta-adrenergic blocker sotalol from blood and urine. J Pharm Sci 60: 833–839
Gibaldi M, Perrier D (1975) Drugs and the pharmaceutical sciences, Vol 1: Pharmacokinetic. Marcel Dekker, New York, pp 45–95
Ibsen H, Sederberg-Olsen P (1973) Changes in the glomerular filtration rate during long term treatment with propranolol in patients with arterial hypertension. Clin Sci 44: 129–134
Marquardt D W (1963) An algorithm for least-squares estimation of non-linear parameters. J Soc Ind Appl Math 11: 431–440
McDevitt D G, Shanks R G (1977) Evaluation of once daily sotalol administration in man. Br J Clin Pharmacol 4: 153–156
Parvinen I, Paukkala E (1979) Comparison of once and twice daily administration of sotalol in the treatment of hypertension. Eur J Clin Pharmacol 15: 293–298
Sassard J, Pozet N, McAinsh J, Legheand J, Zech P (1977) Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol 12: 175–180
Shanks RG (1966) Methods for the evaluation of beta-adrenoceptor antagonists. In: Mantegazzi P, Picinini F (eds) Methods of drug evaluation. North Holland, Amsterdam, pp 118–126
Shaw H L (1977) Once daily sotalol in the treatment of hypertension. J R Coll Gen Pract 27: 752–745
Simpson F O (1974) Beta-adrenergic blocking drugs in hypertension. Drugs 7: 85–105
Sundquist H, Anttila M, Arstila M (1974) Antihypertensive effects of practolol and sotalol. Clin Pharmacol Ther 16: 465–472
Sundquist H (1976) Pharmacokinetics and hypertensive effect of the beta-blocker sotalol. Jaakko-Taara Oy, Turku
Tjandramaga T B, Thomas J, Verbeeck R, Verbesselt R, Verberckmoes R, de Schepper P J (1976) The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 3: 259–265
Tuomilehto J, Arstila M, Sarilahti R, Sundquist H (1977) Sotalol and a combination of hydrochlorothiazide and spironolactone in the treatment of hypertension with a single daily dose. Curr Ther Res Clin Exp 21: 668–675
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berglund, G., Descamps, R. & Thomis, J.A. Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency. Eur J Clin Pharmacol 18, 321–326 (1980). https://doi.org/10.1007/BF00561389
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561389